Booster immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2014-2019

Background Despite China’s Expanded Program on Immunization (EPI) provides 2 doses of group A and group C meningococcal polysaccharide vaccine (MPV-AC) for children at 3 years and 6 years old, more self-paying group ACYW135 meningococcal polysaccharide vaccines (MPV-ACYW135) have been used as an alternative to MPV-AC to prevent Neisseria meningitidis serogroup C,Y,W135. We provide recommendations for Chinese booster immunization of meningococcal meningitis vaccine by analyzing the service status of MPV-AC and MPV-ACYW135. Methods Reported data of routine immunization coverage from all districts of Hangzhou registered in the China Information Management System For Immunization Programming (CIMSFIP) between 2014 to 2019 were described and evaluated. Descriptive epidemiological methods were used to characterize the data. Adverse event following immunization (AEFI) were collected from Chinese national adverse event following immunization information system (CNAEFIIS) to compare the safety of MPV-AC and MPV-ACYW135. Results 1376919 doses of booster immunization of meningococcal meningitis vaccine (MenV) in CIMSFIP were conducted in China Hangzhou from 2014 to 2019, with reported immunization coverage rates above 95%. The proportion of children using MPV-ACYW135 increased from 12.63% in 2014 to 29.45% in 2019. The incidence of AEFI of MPV-AC and MPV-ACYW135 were 49.75 per 100,000 and 45.44 per 100,000, respectively, without statistical difference. Conclusion Children in Hangzhou had high booster immunization of MenV coverage. The use amount and use rate of MPV-ACYW135 increased year by year, indicating more and more parents had chosen MPV-ACYW135 as an alternative to MPV-AC at their own expense for children. The use proportions of MPV-ACYW135 were different in urban, suburban and rural areas. Both MPV-AC and MPV-ACYW135 were safe for children.

Download Full-text

Immunization Coverage and Antibody Retention against Rabies in Domestic Dogs in Lusaka District, Zambia

Pathogens ◽

10.3390/pathogens10060738 ◽

2021 ◽

Vol 10 (6) ◽

pp. 738

Author(s):

Chiho Kaneko ◽

Michihito Sasaki ◽

Ryosuke Omori ◽

Ryo Nakao ◽

Chikako Kataoka-Nakamura ◽

...

Keyword(s):

Antibody Titer ◽

Neutralizing Antibodies ◽

Herd Immunity ◽

Immunization Coverage ◽

Survey Method ◽

Booster Immunization ◽

Antibody Titers ◽

Single Vaccination ◽

Expanded Program On Immunization ◽

Over Time

Rabies remains endemic in Zambia. Despite conducting canine vaccinations in Lusaka district, the vaccination coverage and actual seropositivity in the dog population in Lusaka district are rarely evaluated. This study estimated the seropositivity-based immunization coverage in the owned dog population in Lusaka district using the expanded program on immunization cluster survey method. The time-series trend of neutralizing antibodies against rabies in vaccinated dogs was also evaluated. Of 366 dogs in 200 dog-owning households in Lusaka district, blood samples were collected successfully from 251 dogs. In the sampled dogs, 42.2% (106/251) had an antibody titer ≥0.5 IU/mL. When the 115 dogs whose blood was not collected were assumed to be seronegative, the minimum immunization coverage in Lusaka district’s owned dog population was estimated at 29.0% (95% confidence interval: 22.4–35.5). It was also found that a single vaccination with certified vaccines is capable of inducing protective levels of antibodies. In contrast, higher antibody titers were observed in multiple-vaccinated dogs than in single-vaccinated dogs, coupled with the observation of a decline in antibody titer over time. These results suggest the importance of continuous booster immunization to maintain herd immunity and provide useful information to plan mass vaccination against rabies in Zambia.

Download Full-text

Factors associated with Complete Immunization Coverage of Children up to the Age of 2 Years in Rural Areas of Varanasi District, Uttar Pradesh

Contemporary Social Sciences ◽

10.29070/27/57207 ◽

2018 ◽

Vol 27 (1) ◽

pp. 1-14

Author(s):

Vineeta Singh ◽

Manushi Srivastava ◽

S. P. Singh ◽

T. B. Singh

Keyword(s):

Rural Areas ◽

Uttar Pradesh ◽

Immunization Coverage ◽

Factors Associated

Download Full-text

Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation

Vaccine ◽

10.1016/j.vaccine.2012.12.014 ◽

2013 ◽

Vol 31 (6) ◽

pp. 994-1007 ◽

Cited By ~ 48

Author(s):

Francesca Poli ◽

Sebastiaan Overeem ◽

Gert Jan Lammers ◽

Giuseppe Plazzi ◽

Michel Lecendreux ◽

...

Keyword(s):

Adverse Event ◽

Data Collection ◽

Case Definition ◽

Adverse Event Following Immunization

Download Full-text

Immunization stress-related response – Redefining immunization anxiety-related reaction as an adverse event following immunization

Vaccine ◽

10.1016/j.vaccine.2020.02.046 ◽

2020 ◽

Vol 38 (14) ◽

pp. 3015-3020 ◽

Cited By ~ 5

Author(s):

Michael S. Gold ◽

Noni E. MacDonald ◽

C. Meghan McMurtry ◽

Madhava Ram Balakrishnan ◽

Ulrich Heininger ◽

...

Keyword(s):

Adverse Event ◽

Adverse Event Following Immunization ◽

Related Response ◽

Related Reaction

Download Full-text

Vasculitis as an adverse event following immunization – Systematic literature review

Vaccine ◽

10.1016/j.vaccine.2015.09.026 ◽

2016 ◽

Vol 34 (51) ◽

pp. 6641-6651 ◽

Cited By ~ 21

Author(s):

Caterina Bonetto ◽

Francesco Trotta ◽

Patrizia Felicetti ◽

Graciela S. Alarcón ◽

Carmela Santuccio ◽

...

Keyword(s):

Adverse Event ◽

Literature Review ◽

Systematic Literature Review ◽

Adverse Event Following Immunization

Download Full-text

Improving Immunization Coverage in Rural Areas of Ecuador: A Cost-Effectiveness Analysis

Tropical Doctor ◽

10.1177/004947550103100107 ◽

2001 ◽

Vol 31 (1) ◽

pp. 21-24 ◽

Cited By ~ 16

Author(s):

Miguel San Sebastián ◽

Isabel Goicolea ◽

Jaime Avilés ◽

Mauricio Narváez

Keyword(s):

Cost Effectiveness ◽

Rural Areas ◽

Immunization Coverage ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Subcutaneous nodules: an important adverse event following immunization

Expert Review of Vaccines ◽

10.1080/14760584.2019.1586540 ◽

2019 ◽

Vol 18 (4) ◽

pp. 405-410 ◽

Cited By ~ 3

Author(s):

Rowena Silcock ◽

Nigel W Crawford ◽

Kirsten P Perrett

Keyword(s):

Adverse Event ◽

Subcutaneous Nodules ◽

Adverse Event Following Immunization

Download Full-text

Glycaemic control in type 2 diabetes patients and its predictors: a retrospective database study at a tertiary care diabetes centre in Ningbo, China

BMJ Open ◽

10.1136/bmjopen-2017-019697 ◽

2018 ◽

Vol 8 (3) ◽

pp. e019697 ◽

Cited By ~ 11

Author(s):

Jialin Li ◽

Kaushik Chattopadhyay ◽

Miao Xu ◽

Yanshu Chen ◽

Fangfang Hu ◽

...

Keyword(s):

Physical Activity ◽

Type 2 Diabetes ◽

Glycaemic Control ◽

Rural Areas ◽

Tertiary Care ◽

Fasting Blood Glucose ◽

Information Management System ◽

Cross Sectional ◽

Poor Glycaemic Control

ObjectivesThe objectives of the study were to assess glycaemic control in patients with type 2 diabetes (T2DM) at a tertiary care diabetes centre in Ningbo, China and to determine factors that independently predict their glycaemic control.DesignRetrospective cross-sectional study using an existing database, the Diabetes Information Management System.SettingTertiary care diabetes centre in Ningbo, China.ParticipantsThe study included adult patients with T2DM, registered and received treatment at the diabetes centre for at least six consecutive months. The study inclusion criteria were satisfied by 1387 patients, from 1 July 2012 to 30 June 2017.Primary outcome measureGlycaemic control (poor was defined as glycated haemoglobin (HbA1c)>=7% or fasting blood glucose (FBG)>7.0 mmol/L).ResultsIn terms of HbA1c and FBG, the 5-year period prevalence of poor glycaemic control was 50.3% and 57.3%, respectively. In terms of HbA1c and FBG, the odds of poor glycaemic control increased with the duration of T2DM (>1 to 2 years: OR 1.84, 95% CI 1.06 to 3.19; >2 to 4 years: 3.32, 1.88 to 5.85 and >4 years: 5.98, 4.09 to 8.75 and >1 to 2 years: 2.10, 1.22 to 3.62; >2 to 4 years: 2.48, 1.42 to 4.34 and >4 years: 3.34, 2.32 to 4.80) and were higher in patients residing in rural areas (1.68, 1.24 to 2.28 and 1.42, 1.06 to 1.91), with hyperlipidaemia (1.57, 1.12 to 2.19 and 1.68, 1.21 to 2.33), on diet, physical activity and oral hypoglycaemic drug (OHD) as part of their T2DM therapeutic regimen (1.80, 1.01 to 3.23 and 2.40, 1.36 to 4.26) and on diet, physical activity, OHD and insulin (2.47, 1.38 to 4.41 and 2.78, 1.58 to 4.92), respectively.ConclusionsMore than half of patients with T2DM at the diabetes centre in Ningbo, China have poor glycaemic control, and the predictors of glycaemic control were identified. The study findings could be taken into consideration in future interventional studies aimed at improving glycaemic control in these patients.

Download Full-text